Pharmacovigilance in patients with diabetes: A data-driven analysis identifying specific RAS antagonists with adverse pulmonary safety profiles that have implications for COVID-19 morbidity and mortality
Authors:
- Emma G. StaffordESEmma G. Stafford
- Jim E. RiviereJRJim E. Riviere
- Xuan XuXXXuan Xu
- Jessica KawakamiJKJessica Kawakami
- Gerald J. WyckoffGWGerald J. Wyckoff
- Majid Jaberi-DourakiMJMajid Jaberi-Douraki
Open Access
- 1 November 2020
- journal article
- research article
- Published by Elsevier in Journal of the American Pharmacists Association
- Vol. 60 (6) , e145-e152
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?The Lancet Respiratory Medicine, 2020
- Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, ChinaJAMA, 2020
- Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort studyThe Lancet, 2020
- Standards of Medical Care in Diabetes—2020 Abridged for Primary Care ProvidersClinical Diabetes, 2020
- Novel Data Sharing Agreement to Accelerate Big Data Translational Research Projects in the One Health SphereTopics in Companion Animal Medicine, 2019
- Making Sense of Pharmacovigilance and Drug Adverse Event Reporting: Comparative Similarity Association Analysis Using AI Machine Learning Algorithms in Dogs and CatsTopics in Companion Animal Medicine, 2019
- 2014 Evidence-Based Guideline for the Management of High Blood Pressure in AdultsJAMA, 2014
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- DrugBank: a comprehensive resource for in silico drug discovery and explorationNucleic Acids Research, 2006
- Are all angiotensin-converting enzyme inhibitors interchangeable?JACC, 2001